

Michael P T Lunn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8700653/publications.pdf>

Version: 2024-02-01

96
papers

4,359
citations

159358

30
h-index

118652

62
g-index

100
all docs

100
docs citations

100
times ranked

6039
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. <i>Brain</i> , 2023, 146, 739-748.	3.7	57
2	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , 2022, 269, 1470-1475.	1.8	5
3	CSF biomarkers for dementia. <i>Practical Neurology</i> , 2022, 22, 285-294.	0.5	3
4	Unusual upper limb features in SORD neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 175-177.	1.4	4
5	IgG-exposure and thromboembolic event risk: findings from the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 876-885.	0.9	10
6	Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers. <i>Practical Neurology</i> , 2022, 22, 461-471.	0.5	2
7	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, 682-693.	3.7	221
8	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. <i>Brain</i> , 2021, 144, 357-360.	3.7	77
9	Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 172-176.	0.9	21
10	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. <i>Brain Communications</i> , 2021, 3, fcab168.	1.5	33
11	Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy. <i>Journal of Neurology</i> , 2021, 268, 1485-1490.	1.8	3
12	Preventing expensive harms in Guillain-Barré syndrome. <i>Lancet Neurology</i> , The, 2021, 20, 249-251.	4.9	0
13	Reply: Guillain-Barré syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome and Unclear association between COVID-19 and Guillain-Barré syndrome and Currently available data regarding the potential association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, e47-e47.	3.7	4
14	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Brain</i> , 2021, 144, 1183-1196.	3.7	46
15	Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, 3, e000096.	0.7	4
16	RFC1 expansions are a common cause of idiopathic sensory neuropathy. <i>Brain</i> , 2021, 144, 1542-1550.	3.7	63
17	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1080-1088.	0.9	6
18	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force's Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	1.4	176

#	ARTICLE	IF	CITATIONS
19	Paraproteinaemic neuropathy: MGUS and beyond. <i>Practical Neurology</i> , 2021, 21, 492-503.	0.5	11
20	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€”Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	1.7	153
21	Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single-centre cohort. <i>British Journal of Anaesthesia</i> , 2021, 127, e75-e78.	1.5	4
22	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021, 39, 101070.	3.2	21
23	Influence of IL-6 levels on patient survival in COVID-19. <i>Journal of Critical Care</i> , 2021, 66, 123-125.	1.0	7
24	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099.	1.5	43
25	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. <i>Neurotherapeutics</i> , 2021, 18, 2351-2367.	2.1	12
26	An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 461-468.	1.4	3
27	Predicting long-term trends in inflammatory neuropathy outcome measures using latent class modelling. <i>Journal of the Peripheral Nervous System</i> , 2021, , .	1.4	3
28	Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimerâ€™s disease in the UK. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
29	Original research: Second IVIg course in Guillain-BarrÃ© syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	0.9	34
30	IgM paraproteinâ€”associated peripheral neuropathy: small CD20â€”positive Bâ€”cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. <i>British Journal of Haematology</i> , 2020, 188, 511-515.	1.2	5
31	A case of limbic encephalitis associated with asymptomatic COVID-19 infection. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1229-1230.	0.9	52
32	MRI quantifies lumbosacral nerve root and sciatic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. <i>European Journal of Radiology</i> , 2020, 130, 109164.	1.2	6
33	Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. <i>Muscle and Nerve</i> , 2020, 62, 617-625.	1.0	19
34	High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. <i>Blood Advances</i> , 2020, 4, 2139-2142.	2.5	13
35	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-BarrÃ© syndrome. <i>Journal of Neuroinflammation</i> , 2020, 17, 86.	3.1	44
36	Clinical characteristics, risk factors, and outcomes of POEMS syndrome. <i>Neurology</i> , 2020, 95, e268-e279.	1.5	28

#	ARTICLE	IF	CITATIONS
37	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. <i>Brain</i> , 2020, 143, 3104-3120.	3.7	880
38	Thromboembolic risk with IVIg. <i>Neurology</i> , 2020, 94, e635-e638.	1.5	25
39	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	1.2	38
40	Neurology in the time of COVID-19. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 568-570.	0.9	53
41	High-Dose Methotrexate Based Therapy for the Treatment of Bing Neel Syndrome. <i>Blood</i> , 2020, 136, 12-13.	0.6	1
42	OUP accepted manuscript. <i>Brain</i> , 2020, 143, e101.	3.7	12
43	Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease. <i>Blood</i> , 2020, 136, 27-27.	0.6	1
44	Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
45	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 314-319.	1.4	46
46	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study. <i>PLoS ONE</i> , 2019, 14, e0211184.	1.1	64
47	High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise?. <i>British Journal of Haematology</i> , 2019, 186, e178-e181.	1.2	9
48	Prevalence and Course of Endocrinopathy in POEMS Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2140-2146.	1.8	20
49	Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. <i>Journal of Neurology</i> , 2019, 266, 1067-1072.	1.8	15
50	086...Clinical, investigational and treatment factors do not determine prognosis of patients with inflammatory neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A27.3-A28.	0.9	0
51	Neuropathies and paraproteins. <i>Current Opinion in Neurology</i> , 2019, 32, 658-665.	1.8	13
52	FM1-4...Intraneural perineuriomas: radiologically classic, clinically varied. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, e21.3-e20.	0.9	0
53	Diagnosis of amyloid neuropathy. <i>Practical Neurology</i> , 2019, 19, 250-258.	0.5	17
54	Advances in <sc>POEMS</sc> treatment and the need to define standardised outcome measures. <i>British Journal of Haematology</i> , 2019, 185, 386-388.	1.2	0

#	ARTICLE	IF	CITATIONS
55	CSF Beta-amyloid 1â€“42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. <i>Annals of Surgery</i> , 2019, 269, 1200-1205.	2.1	56
56	High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines. <i>Blood</i> , 2019, 134, 714-714.	0.6	0
57	POEMS neuropathy: optimising diagnosis and management. <i>Practical Neurology</i> , 2018, 18, 278-290.	0.5	17
58	A diagnostic conundrum. <i>Practical Neurology</i> , 2018, 18, 137-142.	0.5	1
59	Amyloid Î² peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 311-321.	1.2	21
60	Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 429.	1.8	21
61	POEMS syndrome. <i>Current Opinion in Neurology</i> , 2018, 31, 551-558.	1.8	24
62	Raised VEGF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e486.	3.1	24
63	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 689-698.	4.9	48
64	Cerebrospinal fluid in the differential diagnosis of Alzheimerâ€™s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	3.0	79
65	Investigation and management of IgM and WaldenstrÃ¶mâ€™s associated peripheral neuropathies: recommendations from the <sc>IWWM</sc> consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	1.2	58
66	The predictive value of T-tau and AB1-42 levels in idiopathic normal pressure hydrocephalus. <i>Acta Neurochirurgica</i> , 2017, 159, 2293-2300.	0.9	19
67	Inhibition of complement in Guillainâ€™BarrÃ© syndrome: the <sc>ICAâ€™GBS</sc> study. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 4-12.	1.4	70
68	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-Î² Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	1.2	6
69	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1297-1302.	1.2	21
70	A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 33-37.	1.4	59
71	Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. <i>The Cochrane Library</i> , 2015, 2015, CD007115.	1.5	294
72	Do cerebrospinal fluid transfer methods affect measured amyloid Î²42, total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	1.2	5

#	ARTICLE	IF	CITATIONS
73	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	1.2	16
74	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 277-288.	1.4	27
75	Future needs in peripheral neuropathy outcome measures. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 341-346.	1.4	0
76	Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 269-276.	1.4	28
77	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 289-295.	1.4	30
78	Outcome measures in neuromuscular disease: is the world still flat?. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 255-259.	1.4	7
79	Endoscopic and Open Release Similarly Safe for the Treatment of Carpal Tunnel Syndrome. A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0143683.	1.1	69
80	Whippits, nitrous oxide and the dangers of legal highs. <i>Practical Neurology</i> , 2015, 15, 207-209.	0.5	109
81	Tremor in Charcot-Marie-Tooth disease: No evidence of cerebellar dysfunction. <i>Clinical Neurophysiology</i> , 2015, 126, 1817-1824.	0.7	22
82	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015, 262, 2722-2730.	1.8	39
83	PERIPHERAL NERVE BING-NEEL SYNDROME. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.59-e4.	0.9	3
84	THE NEUROPATHY SPECTRUM IN WALDENSTRÅM'S MACROGLOBULINAEMIA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.60-e4.	0.9	0
85	Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208215-bcr2014208215.	0.2	7
86	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. <i>American Journal of Human Genetics</i> , 2014, 95, 590-601.	2.6	75
87	SEE NO EVIL, HEAR NO EVIL, SPEAK NO EVIL KEEP IT A SECRET. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.142-e4.	0.9	0
88	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. <i>Brain</i> , 2014, 137, 2178-2192.	3.7	430
89	SENSORY NEURONOPATHY; A CASE REPORT AND A REVIEW OF THE ROLE OF GANGLION NERVE BIOPSY IN DIAGNOSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.127-e2.	0.9	1
90	Tremor in inflammatory neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1282-1287.	0.9	129

#	ARTICLE	IF	CITATIONS
91	Cerebellar learning distinguishes inflammatory neuropathy with and without tremor. <i>Neurology</i> , 2013, 80, 1867-1873.	1.5	30
92	Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. , 2012, , CD002827.		33
93	The International Inflammatory Neuropathy Consortium. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 235-236.	1.4	0
94	Pinpointing peripheral neuropathies. <i>Practitioner</i> , 2007, 251, 67-8, 71-4, 76-7 passim.	0.3	1
95	Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. <i>Brain</i> , 2002, 125, 904-911.	3.7	86
96	Inflammatory and immunological diseases of the nervous system. , 0, , 585-592.		0